why choose us

Course: In Search of the Best Way to Identify Those Who Would Benefit Most From COVID-19 Vaccination—Who Goes First?

CME Credits: 1.00

Released: 2021-04-06

The rapid development of the COVID-19 vaccines and the excellent results from the phase 3 randomized clinical trials, which demonstrated approximately 95% efficacy of both mRNA vaccines for the prevention of severe laboratory-confirmed COVID-19 and even higher efficacy against severe disease and death from COVID-19, led the US Food and Drug Administration to grant both Pfizer-BioNTech and Moderna vaccines emergency use authorization in December 2020. Vaccine rollout in the United States started on December 14, 2020. By March 13, 2021, more than 101 million doses had been given across the United States, and more than 11% of the US population was fully immunized. While this is a remarkable accomplishment, at the current pace of approximately 1.7 to 2.0 million shots daily, it will take 8 months to vaccinate 75% of the population with a 2-dose regimen. That is not nearly fast enough, considering that more transmissible and likely more deadly SARS-CoV-2 variants are spreading fast.


Educational Objective
To identify the key insights or developments described in this article


View Full Course